Evidence map›Paper›PMID 38368569›Full record

ReviewArchives of microbiology2024

A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases.

Cong Xu, Mengqi Hao, Xiaohu Zai, Jing Song, Yuzhe Huang, Shuangying Gui, Juan Chen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cong XuA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Mengqi HaoA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Xiaohu ZaiA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Jing SongA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Yuzhe HuangA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Shuangying GuiA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China.
Juan ChenA. P. College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China. ichenjuan319@163.com.
Anhui University of Traditional Chinese Medicine · CNAnhui University · CN

Funding

Educational Commission of Anhui Province of China 2023AH050826Innovative Talents Support Program of Anhui University of Chinese Medicine 2020rczd005the National Natural Science Foundation of China U21A20406Youth Project of Natural Science Foundation of Anhui Province 2208085QC98
6 · The paper itself

Abstract

The highly diverse microbial ecosystem of the human body colonizes the gastrointestinal tract has a profound impact on the host's immune, metabolic, endocrine, and other physiological processes, which are all interconnected. Specifically, gut microbiota has been found to play a crucial role in facilitating the adaptation and initiation of immune regulatory response through the gastrointestinal tract affecting the other distal mucosal sites such as lungs. A tightly regulated lung-gut axis during respiratory ailments may influence the various molecular patterns that instructs priming the disease severity to dysregulate the normal function. This review provides a comprehensive summary of current research on gut microbiota dysbiosis in respiratory diseases including asthma, pneumonia, bronchopneumonia, COPD during infections and cancer. A complex-interaction among gut microbiome, associated metabolites, cytokines, and chemokines regulates the protective immune response activating the mucosal humoral and cellular response. This potential mechanism bridges the regulation patterns through the gut-lung axis. This paper aims to advance the understanding of the crosstalk of gut-lung microbiome during infection, could lead to strategize to modulate the gut microbiome as a treatment plan to improve bad prognosis in various respiratory diseases.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaRespiratory Tract DiseasesCytokinesHumansLungCytokinesGut-lung axisGut microbiotaInflammationIntestinal microecologyMechanismRespiratory diseases

Identifiers

PMID38368569
OpenAlexW4391917671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.